Vaccination While Using Biologic Therapy for Eczema: What the Evidence Says

November 9, 2026

AI-generated illustration: Dr. Arsy hydration barrier jar

Evidence summary for education only; not individualized medical advice.

The practical question

People receiving biologic therapy for eczema still need routine preventive care. A 2026 review assessed vaccine response and safety considerations during targeted treatment.

Not all vaccines are alike

Inactivated vaccines and live-attenuated vaccines raise different questions. Recommendations depend on the specific medicine, age, immune status, vaccine type and current product label. Findings for one biologic cannot automatically be transferred to another.

Timing matters

Whenever possible, clinicians review immunization status before treatment starts. During therapy, decisions should balance infection risk, urgency and available evidence rather than stopping a medicine without a plan.

Evidence limitations

Studies may be small, measure antibody response instead of clinical protection and include few children. Rare safety outcomes require larger surveillance datasets.

Safety

Patients and caregivers should bring the exact drug name and dosing schedule to the prescriber or vaccination clinician. Do not delay urgent post-exposure care or independently pause treatment.

Bottom line

Vaccination is generally part of comprehensive eczema care, but vaccine type and medication-specific guidance should be reviewed by the treating team.

Related Dr. Arsy research

References

← Back to Doctor's Notes